Uniqure N.V. Up 9.49% To $6.69 After Earnings Miss

Uniqure NV (QURE) missed earnings estimates for Q3 2023 this morning.

Analyst expectations for Uniqure N.V. earnings per share (EPS) were at a loss of $0.85 per share, with the company missing those estimates with a reported EPS loss of $1.88 per share, leading to a negative surprise of $1.03 per share (-121%). Uniqure N.V.'s earnings were down 84% year-over-year as the firm reported an EPS loss of $1.02 per share in its year-ago quarter. The negative annual growth shows the Healthcare company isn't performing well amid current economic conditions.

Consensus analyst estimates were at $29.8 million. The Healthcare company missed on those expectations for its third quarter with revenue of $1.4 million, a negative revenue surprise of $28.4 million (95%). The firm managed negative 3% growth year-over-year due to Uniqure N.V. reporting quarterly revenue of $1.4 million in its year-ago quarter. Uniqure N.V. achieved a lower earnings growth rate than revenue, signaling that the business has not been able to improve its profit margin.

The stock is up 9.49% to $6.69 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Uniqure N.V. a Bullish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 37. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.